Карточка проекта: Chemical Strategy and AI-Enabled Peptide Vaccine Development
ЧАСТЬ СИСТЕМЫ: Платформа пептидных вакцин
ГОТОВНОСТЬ: Перспективная, но с критическими ограничениями, требующими инженерной доработки.
СУТЬ: Разработка комплексных химических и AI-решений для преодоления слабой иммуногенности, HLA-рестрикции и проблем стабильности/доставки с целью создания масштабируемых и эффективных вакцин.
*
Статья: Chemical Strategy and AI-Enabled Peptide Vaccine Development
Peptide vaccines have emerged as a versatile platform complementing traditional vaccines by offering high safety, precise epitope targeting, and ease of manufacturing; however, they suffer from intrinsically weak immunogenicity, human leukocyte antigen (HLA) restriction, and poor *in vivo stability and delivery efficacy*. Addressing these critical limitations requires a multifaceted engineering approach, integrating advanced chemical strategies with the predictive power of artificial intelligence.
From a chemical perspective, enhancing immunogenicity involves precise structural modifications, such as cyclization or multimerization, to improve conformational stability and receptor binding. Furthermore, the rational design of potent adjuvants and advanced delivery systems, including lipid nanoparticles or polymeric microparticles, is crucial for effective antigen presentation and sustained immune stimulation. These chemical engineering efforts aim to protect the peptide from degradation, optimize its pharmacokinetic profile, and ensure efficient uptake by antigen-presenting cells.
Concurrently, AI and machine learning algorithms are revolutionizing the design phase. AI-driven platforms can accurately predict immunogenic T-cell and B-cell epitopes with broader HLA coverage, overcoming the restriction challenge. Beyond epitope selection, AI can optimize peptide sequences for enhanced stability, solubility, and manufacturability, significantly reducing development timelines. Predictive modeling also facilitates the screening of chemical modifications and adjuvant candidates, identifying synergistic combinations that maximize vaccine efficacy. This synergistic application of chemical innovation and AI-driven computational design represents a robust strategy to engineer next-generation peptide vaccines, ready for rapid and broad clinical application.
Источник: https://pubmed.ncbi.nlm.nih.gov/41889758/